Iambic closed an oversubscribed $100 million financing led by Abingworth and Alexandria Ventures to accelerate its multimodal AI drug discovery stack and advance cancer candidates toward the clinic. The company combines Enchant, a clinical‑property prediction transformer, with NeuralPLexer, a physics‑aware protein‑ligand structure model; Iambic cited recent clinical activity for IAM1363 (HER2 inhibitor) and a $25 million partner deal with Revolution Medicines. Iambic plans to apply funds to bespoke model development with partners and to expand internal discovery-to‑IND programs. Investors emphasized the firm’s integration of generative structural prediction and clinical outcome forecasting as a strategy to shorten timelines and cut discovery costs.